Form Type:  8-K
Filing Date:  6/1/2012 
CIK:  0000949858 
Address:  1522 217TH PLACE S.E. 
City, State, Zip:  BOTHELL, Washington 98021 
Telephone:  (425) 487-9500 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.09 (0.86%)  
Trade Time: 
Apr 24  
Market Cap: 
Description of Business
We are a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. We have three product candidates in our pipeline: custirsen, apatorsen and OGX-225, each of which has a distinct mechanism of action and represents a unique opportunity for cancer drug development. Of the product candidates in our pipeline, custirsen and apatorsen are clinical-stage assets. Product Candidates Overview and Recent Developments Our product candidates focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that we believe promote treatment resistance and survival of tumor cells and are over-produced in response to a variety of cancer treatments.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
      Item 5.02 Departure of Directors or Certain Officers; ...
      Item 5.07 Submission of Matters to a Vote of Security Holders.